A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

J Overgaard, H S Hansen, M Overgaard, Lars Bastholt, A Berthelsen, L Specht, B Lindeløv, K Jørgensen

515 Citationer (Scopus)

Abstract

A multicenter randomized and balanced double-blind trial with the objective of assessing the efficacy and tolerance of nimorazole given as a hypoxic radiosensitizer in conjunction with primary radiotherapy of invasive carcinoma of the supraglottic larynx and pharynx.
OriginalsprogEngelsk
TidsskriftRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Vol/bind46
Udgave nummer2
Sider (fra-til)135-46
Antal sider12
StatusUdgivet - 1 feb. 1998

Fingeraftryk

Dyk ned i forskningsemnerne om 'A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85'. Sammen danner de et unikt fingeraftryk.

Citationsformater